Many people with Alzheimer’s disease start to suffer a loss of the brain’s white matter—a key regulator of cognition—long before their disease is diagnosed. What if this loss could be detected early and stopped?
That’s the goal of a research team led by the Case Western Reserve University School of Medicine. The researchers have identified a protein that, when overexpressed in the brain, causes the degeneration of white matter. And they’ve developed and patented a small-molecule drug that they believe could halt this process.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,